AgelessRx says 90-day longevity trial shows early healthspan signals

AgelessRx published results from a 90-day pilot study tied to the XPRIZE Healthspan competition, saying the trial showed preliminary signals across several healthy aging measures in adults ages 60 to 80. The company’s progress also helped it become one of 10 finalists and secure a $1 million Milestone 2 award.

Why it matters: - AgelessRx’s pilot study adds early data to the race to extend healthy aging, especially in people already showing signs of functional decline. - The XPRIZE Healthspan competition is focused on restoring muscle, cognitive and immune function as people age, so even preliminary results can influence which research paths move forward.

What happened: - AgelessRx published results from its 90-day pilot study as part of the XPRIZE Healthspan competition. - The randomized controlled trial tested a multi-intervention longevity strategy in adults ages 60 to 80 with indicators of age-related functional decline. - The company said the study produced preliminary findings across biological age, immune function, muscle health, sleep, cognitive performance and overall quality of life.

The details: - The published results are from a 90-day pilot study, not a full efficacy trial. - AgelessRx said full details of the study design, findings and safety data are available in the published results linked in the announcement. - The pilot findings do not establish efficacy for any individual intervention or combination of interventions. - Individual outcomes may vary. - AgelessRx was selected as one of 10 finalists from more than 600 teams worldwide. - The company also received a $1 million Milestone 2 award to continue its research.

Between the lines: - The announcement signals momentum, but the company is still at an early stage of evidence generation. - The strongest immediate value of the study may be competitive: the results helped AgelessRx advance in a high-profile global prize program. - The focus on multiple healthspan markers suggests the company is testing a broad longevity strategy rather than a single treatment.

What's next: - AgelessRx will use the milestone funding and finalist status to advance its research in the XPRIZE Healthspan competition. - More data from larger or longer studies would be needed to determine whether the pilot signals translate into real-world benefits. - AgelessRx says it will continue research and clinical trials through its longevity platform.

The bottom line: - AgelessRx’s 90-day pilot study produced encouraging early signals, but the company has not shown that any intervention works yet.